PT - JOURNAL ARTICLE AU - Florian Scotte AU - Hélène Simon AU - Philippe Laplaige AU - Eric-Charles Antoine AU - Caroline Spasojevic AU - Nathalie Texier AU - Karine Gouhier AU - Christos Chouaid TI - Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment AID - 10.1136/bmjspcare-2021-003082 DP - 2021 Oct 26 TA - BMJ Supportive & Palliative Care PG - bmjspcare-2021-003082 4099 - http://spcare.bmj.com/content/early/2022/01/16/bmjspcare-2021-003082.short 4100 - http://spcare.bmj.com/content/early/2022/01/16/bmjspcare-2021-003082.full AB - Objectives Febrile neutropenia (FN) commonly occurs during cancer chemotherapy. Prophylaxis with granulocyte colony-stimulating factors (G-CSFs) is known to reduce the severity and incidence of FN and infections in patients with cancer. Despite the proven efficacy, G-CSFs are not always prescribed as recommended. We performed a discrete-choice experiment (DCE) to determine what factors drive the physician preference for FN prophylaxis in patients with cancer undergoing chemotherapy.Methods Attributes for the DCE were selected based on literature search and on expert focus group discussions and comprised pain at the injection site, presence of bone pain, associated fever/influenza syndrome, efficacy of prophylaxis, biosimilar availability, number of injections per chemotherapy cycle and cost. Oncologists, in a national database, were solicited to participate in an online DCE. The study collected the responses to the choice scenarios, the oncologist characteristics and their usual prescriptions of G-CSFs in the context of breast, lungs and gastrointestinal cancers.Results Overall, the responses from 205 physicians were analysed. The physicians were mainly male (61%), with ≤20 years of experience (76%) and working only in public hospitals (73%). The physicians prescribe G-CSF primary prophylaxis for 32% of patients: filgrastim in 46% and pegfilgrastim in 54%. The choice of G-CSF for primary and secondary prophylaxis was driven by cost and number of injections. Biosimilars were well accepted.Conclusion Cost and convenience of G-CSF drive the physician decision to prescribe or not G-CSF for primary and secondary FN prophylaxes. It is important that these results be incorporated in the optimisation of G-CSF prescription in the clinical setting.No data are available. PrefmeG.